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get for vaccine development. Although anti-merozoite antibodies can block invasion in vitro, there is no efﬁcacy
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croscopy revealed that complement-dependent invasion resulted in aggregation of CR1 at the RBC surface in con-
tact with the merozoite. Finally, total anti-P. berghei IgG enhanced parasite growth and C3 deﬁciency decreased
parasite growth in mice. These results demonstrate, contrary to current views, that complement activation in
conjunction with antibodies can paradoxically aid parasites invade RBCs and should be considered in future de-
sign and testing of merozoite vaccines.
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CR11. Introduction
Malaria, a mosquito-borne infectious disease caused by eukaryotic
intracellular protists of the genus Plasmodium, kills close to one million
people worldwide each year, predominantly children under 5 years of
age (Murray et al., 2012; World Health Organization, 2013). Of the
ﬁve species of Plasmodium that can infect humans, infection with Plas-
modium falciparum accounts for the vast majority of deaths worldwide.
Plasmodium's complex life cycle involves invasion of hepatocytes and
red blood cells (RBCs); however, the clinical symptoms arise from the
invasion of RBCs by the asexual blood stage parasite. Antibodies are
thought to play an important role in natural immunity as demonstrated
by the reduction in parasitemia and clinical symptoms in P. falciparum-
infected individuals following passive transfer of immunoglobulins
from semi-immune donors (Cohen et al., 1961; McGregor, 1964a;
Sabchareon et al., 1991). However, the effector mechanisms are poorly
understood.C6860, MC H036, Hershey, PA
. This is an open access article underDevelopment of a vaccine to block RBC invasion has proven to be an
elusive goal. Much of the effort has been focused on the merozoite sur-
face protein 1 (MSP1) and the apicalmembrane antigen1 (AMA1).Mul-
tiple preclinical vaccine studies have demonstrated, using growth
inhibition assays (GIA), that antibodies targeting MSP1 and AMA1 of P.
falciparum have in vitro RBC invasion and growth inhibitory activity
(Angov et al., 2003; Chang et al., 1992; Kennedy et al., 2002). In addition,
some degree of protective immunity has been seen in some animal
models (Darko et al., 2005; Singh et al., 2003; Singh et al., 2006). Unfor-
tunately, to date, these studies have not translated into in vivo efﬁcacy
in human vaccine trials (Ogutu et al., 2009; Sagara et al., 2009; Spring
et al., 2009). Thus, GIA is a poor predictor of blood stage protective im-
mune responses despite the fact that antibodies do inhibit RBC invasion.
The reasons for this discrepancy are unknown.
One possible explanation for this discrepancy came to light as the re-
sult of the discovery that the complement receptor 1 (CR1) is a sialic
acid (SA)-independent receptor for P. falciparum (Spadafora et al.,
2010; Tham et al., 2010). The complement system is part of the innate
immune response and is an important effector armof humoral immuni-
ty. It can be activated via three main pathways: the classical pathway
(CP); the lectin pathway (LP); and the alternative pathway (AP)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the formation of opsonins (C3b, C4b) that promote phagocytosis, induce
lysis by formation of the terminal complement complex (TCC), and pro-
mote an inﬂammatory response (Ricklin et al., 2010). Once bound to the
pathogen, surface C3b and C4b serve as ligands for CR1, which is present
on RBCs as well as most leukocytes (Fearon, 1980; Tas et al., 1999). CR1
also binds complement factors C1q and mannan-binding lectin (MBL)
(Ghiran et al., 2000; Tas et al., 1999).
We hypothesize that P. falciparum is capable of exploiting the
opsonizing qualities of complement deposition on the merozoite sur-
facewhichwill allow it to bind to CR1 and invade via this invasion path-
way. If we are correct, complement activation could negate the
inhibitory activity of anti-merozoite neutralizing antibodies generated
post vaccination or during natural infection.
2. Materials and Methods
2.1. Parasites, Parasite Culture, and RBC Treatment
SA-independent strains (7G8, 3D7, HB3, andDd2NM)were obtained
from theWalter Reed Army Institute of Research. SA-dependent strains
(FVO, Camp, Dd2, and FCR3) were obtained from the Malaria Research
and Reference Reagent Resource Center (BEI Resources, Manassas,
VA). Parasite cultures were maintained at 1–4% hematocrit (Hct) in
O+bloodwith 10%heat-inactivated (HI) plasma in RPMI 1640Medium
(Sigma-Aldrich, St. Louis, MO) with 25 μg/ml gentamicin, 20 μg/ml hy-
poxanthine, and 7.5% w/v NaHCO3 (complete media) in malaria gas
(5% O2, 5% CO2, and 95% N) at 37 °C. Cultures were synchronized twice
aweek by 5% sorbitol lysis (Lambros and Vanderberg, 1979). Neuramin-
idase treatment of RBCs was carried out as described (Spadafora et al.,
2010).
2.2. Sera, Complement Factors, and CH50/AH50 Assay
Non-hemolyzed whole blood was collected with a 21 gauge needle
from two O+ volunteers into glass tubes without additives (Becton
Dickinson, Franklin Lakes, NJ) and allowed to clot at room temperature
for 50min. The sampleswere centrifuged at 1300 ×g for 15min and the
serumwas removed and re-centrifuged for 5min again to pellet any re-
sidual RBCs or clot particles. The serum was aliquoted and stored at
−80 °C. Serum was used fresh (FS) or after heat inactivation (HIS) at
56 °C for 30 min in 200 μl aliquots in 1.5 ml polypropylene
microcentrifuge tubes (Denville Scientiﬁc, South Plainﬁeld, NJ). Serum
C2 and Factor B (fB) were selectively inactivated by incubation of
200 μl serum aliquots in 1.5 ml microcentrifuge tubes in a 56 °C water
bath for 3 min with constant mixing (Araujo et al., 1991). Puriﬁed com-
plement factors (C1q, C2, C3, C4) and selectively depleted or inactivated
sera were obtained commercially (CompTech, Tyler, TX). 50% CP and AP
complement hemolytic (CH50 and AH50) assays were performed using
the standard methods described in the literature (Morgan, 2000).
2.3. In Vitro Invasion Assays
Invasion assays were carried out in triplicate wells of a 96-well plate
containing sorbitol-synchronized cultures of late trophozoites or schiz-
onts at 0.5% to 2% parasitemia in 2–4% hematocrit. RBCs had amean CR1
expression of 600 molecules per RBC as measured by ﬂow cytometry
(Spadafora et al., 2010). Inhouse prepared serum (FS or HIS)was always
autologous to the RBCs used in the assays. Complement-depleted or C3/
C4-inactivated sera were always commercially-obtained (CompTech,
TX) and came from pooled donor blood, and was thus, heterologous to
the RBCs in the assays. Sera were added to a ﬁnal concentration of
10%. The cyclical C3 inhibitor peptide compstatin (NH3-IIe-Cys-Val-
Val-Gln-Asp-Trp-Gly-His-His-Arg-Cys-Thr-COOH) (Tocris Bioscience,
Bristol, UK) (Mastellos et al., 2015), was used to determine the effect
of blocking C3. A peptide derived from the linearized and scrambledsequence of compstatin without cysteins (NH3-Arg-Thr-Ala-Trp-Gln-
His-Asp-Ala-lle-His-Val-Gly-Val-COOH) was synthesized and used as a
control. sCR1 was used as an inhibitor (Celldex Therapeutics, Hampton,
NH) and fetuin (Sigma-Aldrich, St. Louis, MO), an inert glycoprotein
with no complement activity, was used as negative control protein
where appropriate. Antibodies were added at different concentrations.
Mousemonoclonal antibodymAb5.2was raised against the 19 kDa sub-
unit of the merozoite surface protein 1 (MSP119) (Siddiqui et al., 1986)
and was puriﬁed from cultured hybridoma by protein A/G chromatog-
raphy (Thermo Fisher Scientiﬁc, Rockford, IL). Mouse IgG2b Clone
eBMG2b (eBioscience, San Diego, CA) was used as isotype control. IgG
from individuals vaccinated with MSP142 (Otsyula et al., 2013), com-
prising the C-terminal 42-kDa portion of the FVO variant of P. falciparum
MSP1, was puriﬁed by protein A/G chromatography. The plate was
placed in a gas-impermeable heat-sealable bag and inﬂatedwithmalar-
ia culture gas (Haynes et al., 2002). As an alternative procedurewe used
ﬁlter-puriﬁed merozoites as described by Boyle et al. (2010, 2015) with
the exception that late trophozoite/schizonts were enriched using a
Percoll gradient (Moll et al., 2008). After 20 to 24 h, 5 μl aliquots of indi-
vidual wells were added to 100 μl 5 μg/ml Hoechst 33342 (Life Technol-
ogies, Grand Island, NY) in PBS containing 2% paraformaldehyde
(Sigma-Aldrich). At least 100,000 RBCs were acquired for each sample.
Acquisition was done using a LSRII ﬂow cytometer (Becton Dickinson,
Franklin Lakes, NJ) equipped with a violet laser and analysis was per-
formed using FCS Express (De novo Software, Glendale, CA). RBCs
with Hoechst-positive ring stage parasitemia (early trophozoite) were
used as endpoint for 24-h invasion assays. The background staining of
an uninfected RBC sample was subtracted. The majority of the experi-
ments were repeated 2–3 times.
2.4. Merozoite Attachment Assay
Unless otherwise stated, all the centrifugation steps were at 770 ×g
for 5 min at room temperature (RT). Attachment assays were carried
out as invasion assays except that highly synchronous late stage parasite
cultures were incubatedwith 10 μg/ml of leupeptin (Sigma-Aldrich) for
6 to 8 h followed by three washes with RPMI 1640. The hematocrit was
adjusted to 2% by the addition of fresh RBCs. The ﬁnal culture medium
also contained 2 μM cytochalasin D (Sigma-Aldrich) and 10% comple-
ment deﬁcient or reconstituted serum in the presence or absence of
mouse mAb5.2 or IgG2b. The cultures were incubated again for 3–4 h
at 37 °C in malaria gas followed by centrifugation at 400 ×g for 1 min
at 4 °C and two washes with 100 μl of 1% BSA/PBS blocking buffer.
mAb5.2 (2 mg/ml), if not added previously, and goat polyclonal anti-
C3 (MP Biomedicals, Santa Ana, CA) antibodies diluted 1:33 in blocking
buffer were added for 30 min at 4 °C. Following three washes with
blocking buffer, the pellets were resuspended in 1:100 dilution of don-
key anti-goat IgG-PerCP R&D Systems, Minneapolis, MN) and goat anti-
mouse DyLight 488 (KPL, Gaithersburg, MD) in blocking buffer and in-
cubated for 30 min at 4 °C. After an additional three washes with
blocking buffer the pellets were resuspended in 2% paraformaldehyde/
PBS with 5 μg/ml Hoechst 33342 (Life Technologies) solution. Acquisi-
tion by ﬂow cytometry was carried out as above.
2.5. Confocal Microscopy of Merozoite Attachment
For confocal microscopy of the interaction of merozoites with RBCs
the culture conditions were the same as for attachment assays. After in-
cubation, the pellets were resuspended in 1% BSA/PBS blocking buffer
containing 130 μg/ml mouse anti-MSP1 mAb5.2 (if not present during
the assay), 190 μg/ml of chicken polyclonal anti-CR1 (Gallus
Immunotech, ON, Canada), and 30 μg/ml of mouse monoclonal 1H8
anti-C3 IgG1 (Kerafast, Boston, MA) and incubated for 30 min at 4 °C.
The speciﬁcity of each primary antibody was veriﬁed by the use of neg-
ative control antibodies. After three washes with blocking buffer, the
pellets were resuspended in 100 μl of blocking buffer containing 1:500
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Alexa Fluor 546, and goat anti-mouse IgG1 Alexa Fluor 594 (Thermo
Fisher Scientiﬁc) in the presence of 30 μM Vybrant DID cell labeling so-
lution (Life Technologies) followed by an incubation for 30 min at 4 °C.
After an additional three washes, the pellets were resuspended in 4%
paraformaldehyde with 10 μg/ml Hoechst 33342 (Life Technologies).
Prior to imaging, 10 μl of the cell suspension was transferred to 0.6 ml
microcentrifuge tubes and centrifuged at 200 ×g for 1 min and the pel-
let was resuspended in 10 μl of VectorShield Hard Set (Vector Labs, Inc.,
Burlingame, CA). 4 μl of this suspension was mounted on a slide, cov-
eredwith a cover slip, and allowed to harden for a fewminutes. Fluores-
cence z-series were collected using a LEICA SP8 confocal microscope
(Leica Microscopes Systems Inc., Buffalo Grove, IL) at 40× oil (HC PL
APO CS2 40×/1.30 Oil) immersion. The images were processed using
Imaris (Bitplane, Concord, MA) image processing software.
2.6. Passive Transfer Experiments
Polyclonal anti-Plasmodiumberghei antibodywas generated by three
cycles of infection and treatment of C57BL/6 Jmice (The Jackson Labora-
tory, Bar Harbor, ME). For the initial infection mice were injected intra-
peritoneally with 1 × 106 P. berghei ANKA IRBC. Parasitemia was
monitored with Giemsa smears and once it reached (5%–10%) the
mice were treated with sub-curative one intramuscular dose of chloro-
quine (500 μg/mouse) for three consecutive days. The parasitemia was
allowed to rebound and the cycle was repeated for a total of 3 times.
For the ﬁnal treatment, mice were treated daily for one week and
allowed to rest for twoweeks. Plasmawas collected frommice by cardi-
ac puncture in citrate phosphate dextrose solution (CPD) (Sigma-Al-
drich) and total antibody was puriﬁed using protein A/G columns
(GenScript, Piscataway, NJ). Antibody puriﬁed from uninfected mice
served as control. For passive transfer experiments wild type or C3 deﬁ-
cientmice of C57BL/6J backgroundwere injectedwith 1.5 × 107 IRBCs in
100 μl of RPMI 1640 in one retro-orbital plexus and with 100 μl of anti-
Pb, control antibodies, or 100 μl of PBS in the contralateral plexus.
Parasitemia was monitored by staining tail vein blood with Hoechst
33342 (2 μg/ml in PF) (Life Technologies) at pre-determined intervals
until day 7 post-infection. Acquisition and analysis were performed as
described above.
2.7. Ethics Statement
The use of human serum and plasma reported here was carried
under human subject research exemptions by theWalter Reed Army In-
stitute of Research Human Subject Research Review Board and by the
Penn State Hershey Medical Center Institutional Review Board that
allowed the use of unidentiﬁed serum and plasma samples. Themalaria
vaccine serum samples were collected originally using protocols ap-
proved by the Walter Reed Army Institute of Research Human Subject
Research Review Board and adhered to the principles of the Declaration
of Helsinki. All animal experiments were carried under protocols ap-
proved by the Penn State Hershey Medical Center Institutional Animal
Care and Use Committee and adhered to NIH guidelines for care and
use of laboratory animals.Fig. 1. FS and anti-merozoitemonoclonal antibodymAb5.2 enhance P. falciparum invasion
of RBCs relative to HIS. a) Two SA-independent strains of P. falciparum, 7G8 and 3D7, were
tested in the presence of 10% FS, 3 min HIS, 5 min HIS, or 30 min HIS. Invasion of RBCs
decreased with progressively longer heat inactivation times. b) Invasion of RBCs in the
same experiment as panel A expressed as percent enhancement relative to 30 min HIS.
See Fig. S3 for additional replicates. c) Invasion of P. falciparum strain 7G8 was tested in
the presence of monoclonal anti-merozoite surface protein 1(MSP1) mAb5.2 (40 μg/ml),
an isotype control antibody (IgG2b), or PBS in 10% FS or 30 min HIS. Invasion of RBCs is
expressed as percent enhancement in FS relative to 30 min HIS. Each panel depicts a
representative experiment. See Fig. S5 for absolute parasitemia and one additional
replicate. Error bars represent standard deviations for triplicate wells. P values were
obtained by one-way ANOVA with post-hoc comparisons.
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Statistical analysis was done with SigmaPlot v11.2 (Systat Software,
San José, CA). Means of normally distributed continuous numeric vari-
ables from two groups were compared using t-test or paired t-test,
whichever was appropriate. Comparisons across more than two groups
were done using analysis of variance with post-hoc Holm-Sidak tests.
Differences in categorical variables were analyzed using chi-square
with Fisher's exact test. All tests were two-tailed α b0.05.Fig. 2. Enhancement of RBC invasion by anti-merozoite monoclonal antibody mAb5.2 is
complement dependent. a) Addition of C2 and fB rescued RBC invasion enhancement
properties of mAb5.2 in 3 min HIS. Invasion of P. falciparum strain 7G8 was tested in the
presence of 40 μg/ml anti-MSP1 mAb5.2, 40 μg/ml IgG2b isotype control, or PBS in the
presence of 10% FS, 3 min HIS, or 30 min HIS. C2 and fB were added to a ﬁnal
concentration of 25 μg/ml and 200 μg/ml respectively. The glycoprotein fetuin was used
as a control at 225 μg/ml. Fig. S6A shows the absolute parasitemia. Additional replicates
are shown in Fig. S7. b) Enhancement of RBC invasion by anti-MSP1 mAb5.2 was
eliminated by the peptide complement inhibitor compstatin but not by control peptide.
Conditions were the same as panel A. Invasion of RBCs is expressed as percent
enhancement relative to 30 min HIS. Fig. S9A shows the absolute parasitemia. Additional
replicates are shown in Fig. S9B and S9C·Error bars represent standard deviations of
triplicate wells. P is based on two-sample t-test for the comparison between mAb5.2
and IgG2b or PBS.3. Results
3.1. Invasion of RBCs is Enhanced by Fresh Serum and Anti-merozoite
Monoclonal Antibody mAb5.2 Relative to Heat-inactivated Serum
To test the hypothesis that complement can enhance RBC invasion,
we ﬁrst evaluated the effect of heat inactivation of serum on invasion.
Although traditional methods of complement inactivation utilize
30min heat treatment at 56 °C, this duration of heat treatment likely re-
sults in the inactivation of multiple enzymes in the complement path-
way. Thus, in order to achieve a more selective inactivation, we also
incubated serum for 3 min and 5 min at 56 °C (Araujo et al., 1991)
and conﬁrmed inactivation by measuring CH50 and AH50 (Fig. S1A
and S1B). Fig. 1a shows the ring parasitemia of overnight RBC invasion
in the presence of 3, 5 or 30 min HIS or FS. Since heat inactivation of
serum is standard in most malaria cultures or GIA (Moll et al., 2008),
from this point forward we present the data as enhancement relative
to 30minHIS (Fig. 1b). The use of FS resulted in a 40% invasion enhance-
ment relative to 30minHIS. This enhancementwas not due to excessive
RBC lysis in the FS wells since the level of free hemoglobin was very low
and similar between HIS and FS (Fig. S2). A drastic reduction in invasion
enhancementwas observedwith just 3 or 5min HIS (Fig. 1b). Addition-
al replicates are shown in Fig. S3. These results suggest that complement
may be involved inmediating the enhancement of invasion observed in
FS relative toHIS. Further, wewere also able to identify enhanced C3de-
position on single merozoites after incubation in FS but not in 30 min
HIS (Fig. S4).
In order to determine whether activation of complement via the
classical pathway by anti-merozoite antibodies could enhance invasion,
we used mAb5.2, raised against the C-terminal 19 kD fragment of P.
falciparum Uganda-Palo Alto MSP1 (Kaslow et al., 1994; Siddiqui et al.,
1986). This antibody was selected due to its availability and relative
ease of production. Fig. 1c shows that addition ofmAb5.2 resulted in sig-
niﬁcant enhancement of invasion above fresh serum. Fig. S5 shows the
absolute parasitemia for Fig. 1c and one additional replicate.
3.2. Enhancement of Invasion by Anti-merozoite Monoclonal Antibody
mAb5.2 is Complement-dependent
Using CH50 we conﬁrmed that we could reverse the 3 min heat in-
activation of complement by addition of C2 (Fig. S1A) (Araujo et al.,
1991). Therefore, we tested the effect of 3 min HIS on the ability of
mAb5.2 to enhance parasite invasion of RBCs. Use of 3minHIS abolished
the antibody-mediated enhancement of invasion (Figs. 2a and S6).Fig. 3. Enhancement of RBC invasion by mAb5.2 is abolished in the presence of sCR1.
Invasion of P. falciparum strain 7G8 was tested in the presence of 40 μg/ml anti-MSP1
mAb5.2 or 40 μg/ml IgG2b isotype control in the presence of 10% FS or 30 min HIS. The
ﬁnal concentration of sCR1 or fetuin was 80 μg/ml. Fig. S10 shows the absolute
parasitemia and additional replicates. Error bars represent standard deviations of
triplicate wells. P is based on two-sample t-test.
Fig. 4. SA-dependent strains of P. falciparum are more reliant on complement to invade
NA-treated RBCs than SA-independent strains. a) SA-dependent strains show greater
enhancement of invasion into NA-treated RBC (median 54.8%) in the presence of FS
relative to 30 min HIS than SA-independent strains (median 31.5%), P b 0.01 by two-
sample t-test. Fig. S11 shows absolute parasitemias. Fig. S12 shows one additional
replicate. b) Enhancement of invasion into NA-treated RBCs in the presence of C3/C4-
reconstituted serum relative to C3/C4-inactivated serum. Fig. S11C shows absolute
parasitemias. Error bars are standard deviations of triplicate wells. P values are based on
two-sample t-test.
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3 min HIS rescued antibody-mediated enhancement of invasion but
had no effect in the absence of antibody or in the presence of an isotype
control (Figs. 2a and S7). Interestingly, C1q or C2-repleted pooled heter-
ologous serum produced minimal level of RBC invasion enhancement
relative to depleted serum (Fig. S8). On the other hand, autologous FS
produced signiﬁcant amount of enhancement relative to HIS (Fig. S8).
The reasons for the lack of enhancement with heterologous serum are
unclear. However, one possible factor that we are currently investigat-
ing is the role of minor incompatibilities with the donor RBCs.To further conﬁrm that complement is responsible for antibody-me-
diated enhancement of RBC invasion,we used the C3-selective inhibitor
compstatin, a cyclic 13-amino acid peptide that inhibits C3 cleavage and
activation in human serum (Sahu et al., 1996). Enhancement of invasion
was observed in FS in the presence of mAb5.2. The addition of
compstatin eliminated this enhancement (Figs. 2b and S9). Interesting-
ly, compstatin had no effect on the enhancement of invasion by FS
alone. These results demonstrate that activation of the CP can result in
enhancement of RBC invasion by merozoites.3.3. Soluble CR1 Blocks Enhancement of Invasion by Fresh Serum and Anti-
merozoite Antibodies
To test whether CR1 is involved in complement and antibody-medi-
ated enhancement of RBC invasion by P. falciparumwe used soluble CR1
(sCR1) as an inhibitor. Anti-merozoite antibody-mediated enhance-
ment of RBC invasion was not only negated in the presence of sCR1
but declined below the level of the isotype control IgG2b (Figs. 3 and
S10). There was no effect in the absence of mAb5.2 (Figs. 3 and S10).3.4. SA-dependent Strains Demonstrate Greater Enhancement of Invasion
in the Presence of Complement than SA-independent Strains
P. falciparum can be subdivided into SA-dependent strains that in-
vade neuraminidase (NA)-treated RBCs at a low level and SA-indepen-
dent strains that are able to invade NA-treated RBCs at a higher level
(Mitchell et al., 1986) via CR1 and the merozoite ligand PfRh4 (Tham
et al., 2010). Since SA-dependent strains are unable to utilize PfRh4 for
CR1-mediated invasion (Stubbs et al., 2005), we hypothesized that
these strains may be more reliant on complement to accomplish this
function. Hence, we compared invasion levels of SA-dependent and
SA-independent strains in fresh and 30 min HIS in untreated and NA-
treated RBCs. SA-dependent strains demonstrated greater enhance-
ment of invasion with fresh serum compared to HIS in NA-treated
RBCs than SA-independent strains, median enhancement 54.8% vs.
31.5%, P b 0.01 by two-sample t-test (Figs. 4a, S11, and S12). Similar re-
sults, although of lower magnitude, were observed in the presence of
C3/C4-inactivated vs C3/C4-reconstituted heterologous pooled serum
(Fig. 4b and S11C).3.5. Anti-merozoite mAb5.2 Enhances Merozoite Attachment to RBCs and
Induces CR1 Aggregation in a Complement-dependent Manner
To address the question of whether the presence of complement en-
hances the binding of merozoites to the RBC surface we performed at-
tachment assays. In order to inhibit merozoite invagination we
allowed merozoites to egress in the presence of cytochalasin D (Miller
et al., 1979), complement deﬁcient or reconstituted serum, and either
mAb5.2 or IgG2b isotype control. We then detected RBCs with surface
merozoites with mAb5.2 by ﬂow cytometry. As expected, in the pres-
ence of mAb5.2 and deﬁcient serum reconstituted with either C3/C4
or C3, we observed a signiﬁcantly greater percent of RBCs with attached
merozoites and surface C3 than in the presence of IgG2b isotype control
and complement deﬁcient serum (Fig. 5a andb, and S13), P ≤ 0.01 by
two-sample t-test.
In the interest of depicting the direct interaction of merozoites with
RBCs in the presence of complement andmAb5.2 we performed immu-
noﬂuorescence microscopy. Attachment assays were setup in the pres-
ence of C3-depleted and reconstituted heterologous serum, with or
without mAb5.2. In the presence of C3 andmAb5.2 there was dense ag-
gregation of CR1 and lipids, and C3 deposition at the site of merozoite
contact with the RBC but these ﬁndings were absent in C3-depleted
serum, P b 0.001 by chi-square test (Fig. 5c, d, and e).
Fig. 5.Antibody and complement-mediated attachment ofmerozoites to RBCCR1. Attachment of P. falciparum strain 3D7was tested in the presence of anti-MSP1mAb5.2 or IgG2b isotype
control, in the presence of a) C3/C4-inactivated or C3/C4-reconstituted serumandb) C3-depleted or C3-reconstituted serum. Fig. S13 shows additional replicates. P is based on two-sample
t-test. Error bars represent standard deviations for triplicate wells. c) In the presence of C3 and anti-MSP1 mAb5.2 merozoites attach to RBCs via CR1 (yellow) which shows intense
aggregation at the site of merozoite contact. This area is also positive for C3 (cyan) and shows lipid accumulation by DID staining (red). Hoechst 33,342 was used to stain the DNA
(blue) and MSP1 staining shows green. On the other hand, use of C3-depleted serum resulted in absence of CR1 aggregation, C3 deposition, or lipid accumulation. Scale bar is 2 μm. d)
Zoomed view of C3 deposition (i and iii) and CR1 co-localization (ii and iv) in C3-reconstituted and depleted serum. e) Quantitation of the merozoites with C3 deposition and CR1 co-
localization in C3-reconstituted and depleted serum in the presence of anti-MSP1 mAb5.2. *P b 0.001, by chi-square test with Fisher's exact test, under the null hypothesis that the CR1
and C3b co-localization are equal in complement sufﬁcient and deﬁcient serum.
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MSP1 Antibodies
To assess the role of human antibody-mediated complement activa-
tion on RBC invasion we puriﬁed total IgG from MSP142 vaccines
(Otsyula et al., 2013) and tested it in invasion assays using C3/C4-
inactivated or reconstituted sera. Percent inhibition was calculated rel-
ative to PBS-only since we did not have pre-immunization serum. The
median inhibitory activity in C3/C4-inactivated serum was negligible
but upon reconstitution of serumwith the missing complement factors
the inhibitory activity became negative, signifying invasion enhance-
ment (Fig. 6). There was no difference between C3/C4-inactivated and
reconstituted serum in the presence of IgG from unvaccinated controls.Fig. 6. Complement decreases inhibitory activity of polyclonal IgG fromMSP142 vaccine recipien
ml) from MSP142 vaccine recipients and either C3/C4-inactivated or C3/C4-reconstituted seru
controls, N = 14. Horizontal markers represent medians. P is by paired t-test.3.7. Passive Transfer of Anti-P. berghei Antibodies Enhances Parasitemia
and C3 Deﬁciency Decreases Parasitemia in Mice
To validate the observed in vitro antibody-mediated complement
enhancement of RBC invasion in an in vivo setting we infected C57BL/
6 mice with P. berghei ANKA and administered varying concentrations
of polyclonal total anti-P. berghei IgG (anti-Pb), control total IgG from
naïve mice, or PBS. The anti-Pb antibody resulted in enhancement of
endpoint parasitemia in a reverse dose-dependent manner when com-
pared to the PBS control group (Fig. 7A and B). Additional replicates are
found in Fig. S14. Surprisingly, control antibodies, independent of the
dose administered, produced an inhibitory effect when compared to
the PBS control, P = 0.06 by two-sample t-test.ts. a) RBC invasion of P. falciparum strain FVO in the presence of puriﬁed total IgG (2.5mg/
m, N = 13. b) RBC invasion in the presence of total IgG from malaria naïve non-vaccinee
Fig. 7. Anti-P. berghei antibodies and complement enhance parasite growth in mice. a) Time course of parasite growth in mice injected with anti-P. berghei antibody (Anti-Pb), control
antibody (Cont Ab), or PBS. b) Day 7 enhancement of parasitemia from panel A relative to mice that received PBS. P value is based on analysis of variance. c) Time course of P. berghei
parasitemia in C3–/− (C3 KO) and wild type mice that received 250 μg of Anti-Pb or Cont Ab, or equivalent volume of PBS. d) Day 7 enhancement of parasitemia from panel c. P is
based on two-sample t-test. Additional replicates are shown in Fig. S14. Error bars represent standard errors for each group of 4–5 mice.
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jected C3–/−mice to P. berghei infection in the presence of anti-Pb, con-
trol antibodies, or PBS. Fig. 7C and 7D show that C3–/−mice had blunted
parasite growth relative to theirwild type counterparts across all groups
although it was only statistically signiﬁcant in the case of PBS. C3–/−
mice that received anti-Pb antibody still showed enhancement of
parasitemia although it did not reach statistical signiﬁcance. C3–/−
mice that received control IgG had an intermediate response.
4. Discussion
Antibodies that coat pathogens in the circulation induce activation of
the complement cascade and opsonization with C4b and C3b. Opson-
ized pathogens can bind to CR1 on RBCs via C4b and C3b. When theRBCs traverse through the liver or spleen and encounter macrophages,
attached pathogens are removed by phagocytosis and the RBCs are
spared and recirculate (Davies et al., 1990). This process of binding to
RBCs and removal of opsonized pathogens is beneﬁcial to the host.
However, unlike other pathogens, opsonization of malaria merozoites
may facilitate binding to their ultimate target cell, the RBC. Recently,
two groups (Kennedy et al., 2016; Rosa et al., 2016) reported that the
ﬂuid phase complement regulator Factor H can bind to IRBCs and to
merozoites. Factor H functions to accelerate the degradation of the AP
convertase and as cofactor for the Factor I-mediated cleavage of C3b to
iC3b (Pouw et al., 2015). Since CR1 is also able to bind iC3b (Nilsson et
al., 2011), Factor H activity could lead to the accumulation of this mole-
cule on the merozoite surface and enhance binding to CR1. Therefore,
we reasoned that opsonization of merozoites may enhance RBC
214 S. Biryukov et al. / EBioMedicine 9 (2016) 207–216invasion. Enhancement of invasion by complementhas been reported in
other pathogens such as Leishmania (Da Silva et al., 1989; Datta and
Rappaport, 2006; Schlesinger et al., 1990; Schlesinger, 1993).
To investigate the role of complement in RBC invasion by merozo-
ites, we evaluated the effect of serum in the absence or presence of
anti-merozoite antibodies. Because heat treatment at 56 °C is the tradi-
tional way to inactivate complement, we ﬁrst compared FS to 56 °C HIS.
We showed that FS enhances RBC invasion relative to 3, 5, and 30 min
HIS. Although we were able to restore the CH50 activity of 3 min HIS
by addition of C2 (Fig. S1A), addition of C2 and/or fB to 3 min HIS did
not rescue RBC invasion enhancing activity. One possible explanation
is that 3min heat inactivationmay also inactivate elements of the LPup-
stream of C2 that are activated by merozoites such as mannose binding
lectin associated serine proteases (MASPs).
In order to test the effect of anti-merozoite antibodies in comple-
ment-mediated RBC invasion we used two types of antibodies, an
anti-merozoite mouse monoclonal (mAb5.2) and polyclonal IgG from
MSP142 vaccines (Otsyula et al., 2013). Use of mAb5.2 resulted in en-
hancement of RBC invasion above that of FS alone. 3min HIS eliminated
this enhancement and addition of both C2 and fB was required for res-
cue. Because C2 is an integral part of the CP and fB of the AP ampliﬁca-
tion loop, these data provide strong evidence that both of these
pathways of complement activation play a role in antibody-mediated
enhancement of RBC invasion. The involvement of the CP is not surpris-
ing given its reliance on antibodies. However, antibodies are also known
to play an important role in stabilizing the nascent AP convertase (Lutz
and Jelezarova, 2006). In addition, the AP serves as the main ampliﬁca-
tion loop for the majority of complement deposition even when the CP
is the initial source of complement activation (Harboe et al., 2004;
Harboe and Mollnes, 2008). The important role of C3 was further dem-
onstrated by the effect of the C3 speciﬁc inhibitor compstatin. Use of this
inhibitor eliminated antibody-mediated enhancement of invasion (Fig.
2b). Although compstatin had no effect on enhancement by FS alone,
we cannot rule out that other complement factors such as C1q, MBL,
or C4 also play a role here. Our experiments using single factor depleted
and reconstituted heterologous serum (Fig. S8) suggest that heterolo-
gous serum is not as effective as autologous FS in producing enhance-
ment of invasion. Possible reasons include the presence of minor
incompatibilities between serum and RBCs or residual effects from the
method of depletion. Thus, further studies should be done with single
factor-depleted autologous serum. Enhancement of invasion has been
described with the use of antibodies that block other antibodies that in-
hibit the processing ofMSP1 (Guevara Patino et al., 1997). However, the
mechanism that we describe here is clearly different.
In an effort to validate the relevance of antibody and complement-
mediated enhancement of RBC invasion in humans we puriﬁed total
IgG from serum from MSP142 vaccine recipients collected two weeks
after three doses of vaccine (Otsyula et al., 2013). Due to the limited
amounts of sample obtained we were unable to carry out extensive as-
says. Nonetheless, we measured the RBC invasion inhibitory activity of
total IgG in C3/C4-inactivated or reconstituted serum. Consistent with
previous results (Otsyula et al., 2013),we found very little inhibitory ac-
tivity in total IgG. However, unlike IgG from non-immunized controls,
IgG from vaccine recipients showed reversal of inhibitory activity and
enhancement of RBC invasion upon reconstitution of serum with C3/
C4. Thus, these results demonstrate that enhancement of RBC invasion
can occur with human anti-merozoite antibodies.
Contrary to our data, Boyle et al. (Boyle et al., 2015) recently report-
ed that complement activation enhances the inhibitory activity of
human anti-merozoite antibodies. They determined that the critical in-
hibitory step was ﬁxation of C1q on the merozoite surface. One major
difference between the approach of these investigators and ours is
their use of ﬁlter-puriﬁed merozoites as opposed to allowing merozo-
ites to naturally egress from schizonts. Consequently, we carried out in-
vasion assays with ﬁlter-puriﬁedmerozoites as described by Boyle et al.
(Boyle et al., 2015).We showed thatﬁltered-puriﬁedmerozoites appearto be highly defective and more sensitive to complement activation
than naturally egressed merozoites (Fig. S15).
To demonstrate the role of CR1 in the process of complement-medi-
ated invasion we used sCR1 as a competitor. We observed that in the
presence of sCR1 there was not only complete reversal of antibody-me-
diated enhancement in FS but signiﬁcant amount of inhibition was ob-
served in comparison to the isotype (Fig. 3). The inhibitory activity of
sCR1 may be attributed to its diverse functions. Firstly, sCR1 competes
for binding sites with erythrocyte surface CR1, which may potentially
form large C3b-sCR1 complexes on the merozoite surface and induce
steric hindrance of ligand receptor interactions in the presence of
these complexes. Secondly, sCR1 is able to bind to PfRh4 on themerozo-
ite surface thereby inhibiting the direct interaction of erythrocyte sur-
face CR1 with PfRh4. Thirdly, sCR1 possesses complement regulatory
activity by destabilizing membrane assembled C3 convertases through
its intrinsic decay accelerating activity and by acting as a cofactor for
Factor I, which breaks down C3b into iC3b. The role of CR1 in comple-
ment-dependent invasion was further supported by our co-localization
studies that clearly show aggregation of CR1 at the site of merozoite at-
tachment but only in the presence of C3.
PfRh4 has been proposed as the native merozoite ligand that binds
to CR1. SA-dependent strains of P. falciparum are unable to use this li-
gand (Stubbs et al., 2005). Therefore, we hypothesized that SA-depen-
dent strains may be more reliant on complement to use this invasion
pathway. Although the invasion of NA-treated RBCs by SA-dependent
strains is low, the percent enhancement of invasion in the presence of
FS is signiﬁcantly greater than SA-independent strains. These data dem-
onstrate that, for some strains, C3 can act as the sole CR1 ligand.
Lastly, our passive transfer experiments in mice conﬁrm that anti-
malaria antibody and complement can beneﬁt parasite growth. Admin-
istration of anti-Pb IgG enhanced parasite growth in a reverse dose-de-
pendentmanner. Atﬁrst look, these results stand in contrast to previous
studies that have shown that antibody from immune rodents inhibits
growth in vivo when given to naïve animals (Cavinato et al., 2001;
Jarra et al., 1986; Rotman et al., 1998; Waki et al., 1995; Yoneto et al.,
2001). However, the doses of antibody in those studies were much
higher, usually given in milligram amounts and sometimes in several
doses prior to and after infection. While mice do not express CR1 on
their RBCs, they do express other complement receptors that can bind
complement such as Crry (Molina, 2002). Several studies have also
shown that passive transfer of total IgG from individuals living in en-
demic areas to acutely infected children can reduce parasitemia, but
this was achieved at 5–10 fold higher doses per Kg than the ones we
have used in our studies (Cohen et al., 1961; McGregor, 1964b;
Sabchareon et al., 1991). It is unlikely that these levels of antibodies
can be achieved by natural infection or by immunization. Thus, it is pos-
sible that low doses of anti-merozoite antibodies enhance parasite
growth in vivo while very high doses are required for true in vivo inhib-
itory activity. By contrast, the inhibitory activity of control polyclonal
antibody may be due to its complement scavenging properties
(Arumugam et al., 2007; Hartung, 2008).
C3–/−mice consistently showed signiﬁcant blunting of parasitemia
relative to wild type mice. Yet, they still showed enhancement of para-
site growth in response to anti-Pb IgG, probably due to residual C4b
opsonizing activity. Previous studies of the role of complement in the
growth of rodent malaria have been inconsistent. Use of cobra venom
factor (CVF) as a complement depleting agent resulted in increased
parasitemia (Ward et al., 1981). However, CVF exerts its action by in-
ducing AP convertase formation and C3 activation which could result
in parasite growth enhancement by increased deposition of C3 frag-
ments on merozoites. Unlike our study, a previous study (Ramos et al.,
2012) reported no change in P. berghei parasitemia in C3–/−mice com-
pared to wild typemice, but in that study quantitationwas done bymi-
croscopy and infection was by intraperitoneal injection. C1q and C2/fB
deﬁciency resulted in minimal increase in Plasmodium chabaudi
parasitemia (Taylor et al., 2001). Thus, further studies of these models
215S. Biryukov et al. / EBioMedicine 9 (2016) 207–216are needed to fully understand the role of complement activation in par-
asite growth.
5. Conclusions
We have demonstrated that merozoites are capable of invading
RBCs via a previously unrecognized antibody and complement-mediat-
ed pathway by binding to CR1. Our ﬁndings are especially relevant to
the efforts of developing an anti-merozoite malaria vaccine since
some antibodies may actually enhance RBC invasion. Based on our ﬁnd-
ingswepropose amodelwhere thepresence of anti-merozoite antibod-
ies can activate complement and lead to binding to and aggregation of
RBC CR1 (Fig. S16). The absence of complement could artiﬁcially en-
hance the inhibitory activity of some antibodies. Thus, complement ac-
tivity should be included in GIA to measure the inhibitory activity of
anti-merozoite antibodies.
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